Cardiovascular consequences of viral infections: from COVID to other viral diseases

Cardiovasc Res. 2021 Nov 22;117(13):2610-2623. doi: 10.1093/cvr/cvab315.

Abstract

Infection of the heart muscle with cardiotropic viruses is one of the major aetiologies of myocarditis and acute and chronic inflammatory cardiomyopathy (DCMi). However, viral myocarditis and subsequent dilated cardiomyopathy is still a challenging disease to diagnose and to treat and is therefore a significant public health issue globally. Advances in clinical examination and thorough molecular genetic analysis of intramyocardial viruses and their activation status have incrementally improved our understanding of molecular pathogenesis and pathophysiology of viral infections of the heart muscle. To date, several cardiotropic viruses have been implicated as causes of myocarditis and DCMi. These include, among others, classical cardiotropic enteroviruses (Coxsackieviruses B), the most commonly detected parvovirus B19, and human herpes virus 6. A newcomer is the respiratory virus that has triggered the worst pandemic in a century, SARS-CoV-2, whose involvement and impact in viral cardiovascular disease is under scrutiny. Despite extensive research into the pathomechanisms of viral infections of the cardiovascular system, our knowledge regarding their treatment and management is still incomplete. Accordingly, in this review, we aim to explore and summarize the current knowledge and available evidence on viral infections of the heart. We focus on diagnostics, clinical relevance and cardiovascular consequences, pathophysiology, and current and novel treatment strategies.

Keywords: Advanced diagnostics; Inflammatory cardiomyopathy; Myocarditis; Treatment strategies; Viral infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • COVID-19 / diagnosis
  • COVID-19 / immunology
  • COVID-19 / therapy
  • COVID-19 / virology*
  • COVID-19 Drug Treatment
  • Cardiomyopathy, Dilated / diagnosis
  • Cardiomyopathy, Dilated / immunology
  • Cardiomyopathy, Dilated / therapy
  • Cardiomyopathy, Dilated / virology*
  • Genetic Therapy
  • Host-Pathogen Interactions
  • Humans
  • Myocarditis / diagnosis
  • Myocarditis / immunology
  • Myocarditis / therapy
  • Myocarditis / virology*
  • Parvoviridae Infections / diagnosis
  • Parvoviridae Infections / immunology
  • Parvoviridae Infections / therapy
  • Parvoviridae Infections / virology*
  • Parvovirus B19, Human / immunology
  • Parvovirus B19, Human / pathogenicity*
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity*

Substances

  • Antiviral Agents